2021
Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.Peer-Reviewed Original ResearchProstate cancer-specific survivalU.S. Preventive Services Task ForceSurvival disparitiesUninsured patientsSocioeconomic quintileProstate cancerInsurance statusMarital statusWorse prostate cancer-specific survivalProstate cancer screening recommendationsCox proportional hazards modelDiagnostic time periodsCancer-specific survivalCancer screening recommendationsProportional hazards modelProstate-specific antigenScreening recommendationsSurvival outcomesInsured patientsWorse outcomesHazards modelPatientsBetter outcomesMedian household incomeUninsured individuals
2020
Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasis
2018
Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer.
Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.6_suppl.202.Peer-Reviewed Original ResearchHigh-risk CaPCAP mortalityM1 diseaseHazard ratioTime-varying Cox proportional hazards modelsHigh-risk prostate cancerCox proportional hazards modelHigh-risk CaP.Post-diagnostic useProstate cancer mortalityUse of statinsPopulation-based studyEffect of statinsProstate cancer metastasisCause of deathProportional hazards modelMetformin useSEER databaseRandomized trialsCancer mortalityProstate cancerMedicare filesStatinsHazards modelMetformin